Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis

Chinese Medical Journal

Volumn 126, Issue 9, 2013, Pages 1683-1688

  Sun, Bing Sheng ^a   You, Jian ^a   Li, Yue ^a   Zhang, Zhen Fa ^a   Wang, Chang Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Invasiveness; Non small cell lung cancer; Osteopontin; RNA interference

Indexed keywords

GELATINASE A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LENTIVIRUS VECTOR; MICRORNA; OSTEOPONTIN; UROKINASE;

ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOPONTIN; RNA INTERFERENCE;

EID: 84876936277     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123465     Document Type: Article

References (30)

1. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 27-41.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002; 8: 904-912.
4. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 2010; 14: 2037-2044.
5. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118.
6. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-869.
7. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004; 5: 355-365.
8. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005; 102: 13212-13217.
9. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008; 48: 1834-1842.
10. Wang CL, Sun BS, Tang Y, Zhuang HQ, Cao WZ. CCR1 knockdown suppresses human non-small cell lung cancer cell invasion. J Cancer Res Clin Oncol 2009; 135: 695-701.
11. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-423.
12. Zhivkova-Galunska M, Adwan H, Eyol E, Kleeff J, Kolb A, Bergmann F, et al. Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biol Ther 2010; 10: 54-64.
13. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18: 3923-3930.
14. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007; 57: 373-380.
15. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009; 4: 1104-1110.
16. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010; 28: 936-941.
17. Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer 2012; Epub ahead of print.
18. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006; 23: 123-133.
19. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005; 26: 741-751.
20. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-5215.
21. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999; 11: 614-621.
22. Liu SJ, Hu GF, Liu YJ, Liu SG, Gao H, Zhang CS, et al. Effect of human osteopontin on proliferation, transmigration and expression of MMP-2 and MMP-9 in osteosarcoma cells. Chin Med J 2004; 117: 235-240.
23. Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting steopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010; 295: 27-37.
24. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012; 72: 1688-1699.
25. Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, Tsai CH, et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2009; 221: 98-108.
26. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11: 4646-4652.
27. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009; 64: 263-270.
28. Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, et al. Overexpression of osteopontin, alphavbeta3 and pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS One 2012; 7: e48575.
29. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010; 28: 936-941.
30. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008; 26: 4771-4776.